- Home
- FTEK vs ITRM Comparison
FTEK vs ITRM Comparison
Compare FTEK & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTEK
- ITRM
- Stock Information
- Founded
- FTEK 1987
- ITRM 2015
- Country
- FTEK United States
- ITRM Ireland
- Employees
- FTEK N/A
- ITRM N/A
- Industry
- FTEK Pollution Control Equipment
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- FTEK Industrials
- ITRM Health Care
- Exchange
- FTEK Nasdaq
- ITRM Nasdaq
- Market Cap
- FTEK N/A
- ITRM 37.7M
- IPO Year
- FTEK N/A
- ITRM 2018
- Fundamental
- Price
- FTEK $1.00
- ITRM $1.05
- Analyst Decision
- FTEK Strong Buy
- ITRM Strong Buy
- Analyst Count
- FTEK 1
- ITRM 1
- Target Price
- FTEK $4.00
- ITRM $5.00
- AVG Volume (30 Days)
- FTEK 43.6K
- ITRM 300.3K
- Earning Date
- FTEK 05-06-2025
- ITRM 05-12-2025
- Dividend Yield
- FTEK N/A
- ITRM N/A
- EPS Growth
- FTEK N/A
- ITRM N/A
- EPS
- FTEK N/A
- ITRM N/A
- Revenue
- FTEK $25,133,000.00
- ITRM N/A
- Revenue This Year
- FTEK $22.06
- ITRM N/A
- Revenue Next Year
- FTEK $10.39
- ITRM $150.10
- P/E Ratio
- FTEK N/A
- ITRM N/A
- Revenue Growth
- FTEK N/A
- ITRM N/A
- 52 Week Low
- FTEK $0.87
- ITRM $0.81
- 52 Week High
- FTEK $1.34
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- FTEK 52.28
- ITRM 30.57
- Support Level
- FTEK $0.95
- ITRM $1.05
- Resistance Level
- FTEK $1.01
- ITRM $1.16
- Average True Range (ATR)
- FTEK 0.04
- ITRM 0.08
- MACD
- FTEK 0.00
- ITRM -0.00
- Stochastic Oscillator
- FTEK 61.54
- ITRM 0.00
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.